In a groundbreaking announcement that could reshape global cancer treatment, Russia has revealed the development of a new cancer vaccine named Enteromix. This vaccine, designed to treat cancer after diagnosis rather than prevent it, is being hailed as a potential medical revolution—and will reportedly be provided free of charge to patients worldwide once approved.
The announcement was made by Veronika Skvortsova, head of the Russian Federal Medical and Biological Agency (FMBA), during the Eastern Economic Forum held in Vladivostok in early September 2025. According to Skvortsova, Enteromix has completed mandatory preclinical trials and demonstrated “100% efficacy” with zero side effects in a group of 48 colorectal cancer patients. “The vaccine is now ready for clinical use,” she stated, pending final regulatory approval [1][2].
Unlike traditional chemotherapy, which often harms healthy cells alongside cancerous ones, Enteromix uses mRNA technology to train the immune system to recognize and destroy cancer cells. Each dose is personalized, built from RNA extracted from the patient’s own tumor, allowing for targeted treatment with minimal toxicity [2][3].
The vaccine’s initial focus is colorectal cancer—a leading cause of cancer-related deaths globally. However, Russian scientists are already developing variants for glioblastoma (a deadly brain cancer) and ocular melanoma (a rare eye cancer). The vaccine’s ability to shrink tumors by up to 80% and extend survival without triggering harmful side effects has sparked global interest and cautious optimism [2].
Artificial Intelligence has played a key role in accelerating the vaccine’s development. According to Alexander Gintsburg of the Gamaleya National Research Center, AI-powered neural networks helped reduce the time needed to create personalized doses, potentially enabling production within hours [6].
Despite the excitement, international experts urge caution. No peer-reviewed trial data has been published, and the vaccine’s long-term efficacy remains unverified. Still, the promise of a free, personalized cancer vaccine has ignited hope among millions battling the disease.
If approved, Enteromix could mark a turning point in oncology—ushering in a new era of precision medicine, where treatment is tailored to each patient’s genetic profile. For countries with limited access to advanced cancer care, this could be life-changing.
Russia’s bold claim may still face scrutiny, but for now, it offers something rare in the fight against cancer: hope.
